On this page
Key takeaways
● Collagen is exceptionally high in hydroxyproline. The liver metabolises hydroxyproline via glyoxylate to oxalate — a substrate that crystallises with calcium in the kidney.
● The evidence: Knight 2006 showed that a 30 g gelatin dose increased urinary oxalate excretion by approximately 43% in healthy volunteers (1).
● Who is at risk: people with a personal or family history of calcium-oxalate kidney stones. Not applicable to uric acid, cystine, or struvite stone formers (different mechanisms).
● Practical mitigations if you and your nephrologist agree to proceed: 5 g/day (not 10 g), take calcium-containing food with the dose, maintain high hydration (2.5+ litres water daily).
● Alternative product: undenatured Type II collagen (UC-II) at ~40 mg/day is not gram-scale and does not carry the same oxalate load — a defensible alternative for isolated joint goals (6).
Quick answer
If you have a personal or family history of calcium-oxalate kidney stones, this is one of the few supplements where a real metabolic concern exists. Collagen is exceptionally high in hydroxyproline, which the liver converts to oxalate — the Knight 2006 study showed a 30 g gelatin dose raised urinary oxalate excretion by 43%. Discuss with a nephrologist before starting. If approved, keep the daily dose at 5 g rather than 10 g, take calcium-containing food or supplements with the dose to bind dietary oxalate in the gut, and maintain generous hydration (2.5+ litres/day). For uric acid, cystine, or struvite stone types, this concern does not apply. For those seeking joint-only benefits and wanting to avoid the oxalate load entirely, undenatured Type II collagen (UC-II) at ~40 mg/day is a legitimate alternative.
The metabolic pathway that creates the concern
Every gram of hydrolysed collagen contains approximately 130 mg of hydroxyproline — an amino acid that is essentially exclusive to collagen and gelatin in dietary protein. In most amino acids, this concentration would be biochemically unremarkable. Hydroxyproline is different because of what happens to it in the liver.
The metabolic pathway proceeds as follows. Ingested hydroxyproline is absorbed and reaches the liver via portal circulation. Hepatic enzymes (particularly hydroxyproline oxidase) convert hydroxyproline to 4-hydroxy-2-oxoglutarate, which is cleaved by 4-hydroxy-2-oxoglutarate aldolase to produce pyruvate and glyoxylate. The glyoxylate step is critical: glyoxylate can be either detoxified by conversion to glycine (via alanine-glyoxylate aminotransferase, or AGT) or oxidised to oxalate (via lactate dehydrogenase and glycolate oxidase). The balance of these two fates determines how much of the ingested hydroxyproline ends up as oxalate.
Oxalate itself is essentially a metabolic dead end. It has no useful function; it is excreted in the urine. In the kidney tubule, oxalate combines with calcium — of which there is always some in urine — to form calcium oxalate crystals. In most people, urinary flow and citrate (which inhibits crystallisation) keep crystals from aggregating and passing through as microcrystals harmlessly. In some people, the balance tips: crystals aggregate into stones, and the classic clinical presentation of calcium-oxalate nephrolithiasis follows (2).
What the trial evidence actually shows
The load-bearing evidence for the collagen-oxalate concern is Knight and colleagues' 2006 study published in Kidney International (1). Design: five healthy adults each ingested a series of oral challenges including a 30 g bolus of gelatin (a collagen-related protein with similarly high hydroxyproline content). Urinary oxalate and glycolate (a related metabolite) were measured over the following hours.
Result: after the 30 g gelatin dose, 24-hour urinary oxalate excretion increased by approximately 43% compared with control. Urinary glycolate excretion increased even more markedly, consistent with the metabolic pathway described above. The magnitude of the rise was proportional to the hydroxyproline content of the ingested load, not to total protein amount — a specific finding that identified hydroxyproline metabolism as the driver rather than general protein loading.
Two things about this trial are important. First, the dose (30 g of gelatin) is three times higher than typical supplement doses of hydrolysed collagen. Whether a 10 g collagen dose produces a proportional ~14% rise (linear extrapolation) or something smaller (non-linear response) is not directly measured, but linear-adjacent behaviour is a reasonable working assumption. Second, the subjects were healthy volunteers, not stone formers — so the observed urinary oxalate rise is what a normal metabolism produces. In a stone former with any of the risk factors described below, the same urinary oxalate rise happens against a background of already-elevated risk.
Who is actually at risk
This section requires precision because "kidney stones" is a broad label covering several different stone types with different underlying mechanisms. The oxalate concern applies specifically to calcium-oxalate stone formers — the most common type — but not to all stone types.
Calcium-oxalate stones — the population where this matters
Roughly 70–80% of kidney stones in adults are calcium oxalate. Risk factors include: prior calcium-oxalate stone episode (the strongest single predictor), family history of stones, low urinary volume, high urinary oxalate excretion ("hyperoxaluria"), low urinary calcium (surprisingly — see the calcium paradox below), low urinary citrate, and metabolic conditions (primary hyperoxaluria, enteric hyperoxaluria in fat malabsorption, gastric bypass, chronic diarrhoea).
If you have had a calcium-oxalate stone, the risk of a second stone within 5–10 years without preventive intervention is 30–50%. This is the population where the collagen-oxalate concern is real and worth acting on.
Populations where this does not apply
● Uric acid stones (~5–10% of stones) form because of persistently acidic urine, often in the context of gout, diabetes, obesity, or high animal-protein diets. The metabolic pathway is unrelated to oxalate. Collagen's hydroxyproline load does not affect uric acid stone risk (though the general protein load might modestly).
● Cystine stones (~1% of stones) result from cystinuria — an inherited transport disorder — with no relationship to oxalate metabolism. Collagen is not a concern.
● Struvite stones ("infection stones", ~5–10%) form during urinary tract infection with urease-producing bacteria. Unrelated to dietary oxalate. Collagen is not a specific concern; the treatment target is the infection.
● Calcium phosphate stones (~5%) — related to systemic acid-base handling and often to renal tubular acidosis. Not driven by dietary oxalate. Collagen is not a specific concern.
Practical implication: if you have had a kidney stone, the type matters. If you do not know the type, ask your nephrologist or urologist. Stone composition is typically determined either by analysis of a passed stone or inferred from urine and blood biochemistry.
The calcium paradox — why calcium supplements often help
A common misunderstanding worth addressing directly. Many people assume that reducing dietary calcium reduces calcium-oxalate stone risk. Large observational and interventional data show the opposite: higher dietary calcium intake reduces calcium-oxalate stone recurrence risk (3).
The mechanism is intestinal. Dietary calcium binds dietary oxalate in the gut lumen, forming an insoluble calcium-oxalate complex that is excreted in stool without absorption. Reducing dietary calcium increases free oxalate available for absorption, raising urinary oxalate and paradoxically increasing stone risk. This is why nephrologists no longer recommend low-calcium diets for calcium-oxalate stone formers — quite the opposite.
Direct implication for collagen supplementation: taking collagen alongside calcium-containing food or a calcium supplement should meaningfully reduce net oxalate absorption from the collagen dose. This is one of the practical mitigations described below.
Practical mitigations if you and your nephrologist agree to proceed
If you are a calcium-oxalate stone former and, after nephrology consultation, decide the potential benefits of collagen outweigh the incremental oxalate concern, the following mitigations should be part of your protocol.
Keep the daily dose at 5 g/day, not 10 g
The oxalate rise from hydroxyproline is dose-dependent. Halving the collagen dose approximately halves the theoretical urinary oxalate contribution. Five grams per day covers the trial-validated dose for bone (König 2018) — the most substantial evidence-based collagen indication — and delivers meaningful contribution for skin at the low end of the trial range. Above 5 g/day in this population, the risk-benefit calculation deteriorates rapidly.
Take collagen with calcium-containing food
The calcium-paradox mechanism operates in the gut lumen. If collagen is taken with a calcium-containing meal (dairy, calcium-fortified plant milk, cheese) or with a calcium supplement, dietary calcium binds a portion of the oxalate before absorption. This is standard nephrology advice for calcium-oxalate stone formers eating any oxalate-containing food (spinach, rhubarb, etc.), and it applies to hydroxyproline-derived oxalate as well.
Maintain high daily fluid intake — 2.5+ litres of water
Urinary dilution is the single strongest lever against calcium-oxalate stone recurrence. Borghi 1996 showed that a target urinary output of 2.5+ litres per day reduces recurrence risk by roughly 50% (4). Any additional oxalate load (from collagen or from dietary sources) is meaningfully mitigated by higher urinary volume. Aim for pale-yellow urine consistently.
Maintain adequate citrate intake
Urinary citrate inhibits calcium-oxalate crystallisation. Adequate citrate comes from citrus fruits, particularly lemon juice (roughly 2 tablespoons of lemon juice in daily water provides meaningful citrate). Some nephrologists prescribe potassium citrate directly for stone-formers with hypocitraturia. If you are already on potassium citrate, continue as prescribed.
Get baseline and follow-up 24-hour urine collection
For any stone-former considering collagen, the responsible protocol is to get a baseline 24-hour urine collection measuring oxalate, calcium, citrate, uric acid, and volume before starting; then repeat after 4–8 weeks on collagen to assess whether urinary oxalate has risen meaningfully. If it has (defined by your nephrologist), discontinue collagen. If it has not, continued monitoring at 6–12 month intervals is reasonable.
Alternative products for stone-formers
Two options exist for stone-formers who want the specific benefits collagen provides without the gram-scale hydroxyproline load.
Undenatured Type II collagen (UC-II) for joint goals
If your primary collagen goal is knee osteoarthritis pain, undenatured Type II collagen at approximately 40 mg per day works via a completely different mechanism (oral tolerance at Peyer's patches) and does not carry the same oxalate concern (6). The dose is three orders of magnitude smaller — 40 mg versus 10,000 mg — and the hydroxyproline contribution is proportionally trivial. UC-II has independent trial evidence for knee OA pain and is a legitimate alternative for stone-formers with isolated joint goals. See our hydrolysed versus non-hydrolysed article for the mechanism detail.
Non-collagen alternatives for skin and bone
For skin outcomes, topical retinoids and daily sun protection deliver larger effect sizes than any oral collagen. For bone outcomes, the foundation of vitamin D, calcium, weight-bearing exercise, and — where indicated — prescribed pharmacotherapy delivers effect sizes that dwarf collagen supplementation. For stone-formers, doubling down on these non-collagen levers is a rational alternative to collagen supplementation.
What we still don't know
● Whether a 5 g/day collagen dose produces a clinically meaningful oxalate rise in calcium-oxalate stone formers over months to years of continuous use. No long-term trial data addresses this.
● Whether the calcium co-administration mitigation fully offsets the collagen-derived oxalate load in stone-formers. Mechanistically plausible; direct trial evidence is limited.
● Whether specific molecular-weight fractions or peptide profiles produce different oxalate loads per gram of collagen consumed. Not systematically studied.
● Whether marine, bovine, and porcine sources differ meaningfully in hydroxyproline content and consequent oxalate contribution. Likely small differences; not directly compared for this endpoint.
Bottom line
If you have a personal or family history of calcium-oxalate kidney stones, hydrolysed collagen is one of the few supplements where a real metabolic concern exists. The Knight 2006 study showed that gelatin loading substantially raises urinary oxalate excretion via hepatic hydroxyproline metabolism. Do not start hydrolysed collagen without discussing it with a nephrologist. If cleared to proceed, keep the daily dose at 5 g rather than 10 g, take it with calcium-containing food, maintain 2.5+ litres of daily water intake, and consider baseline plus follow-up 24-hour urine collections to monitor urinary oxalate. For isolated joint goals, undenatured Type II collagen (UC-II) at ~40 mg/day is a legitimate alternative that does not carry the same oxalate load. For uric acid, cystine, struvite, or calcium-phosphate stone types, this concern does not apply. See our side effects article for the broader safety picture and the pillar guide for context.
Frequently asked questions
Can hydrolysed collagen cause kidney stones?
In people with a personal or family history of calcium-oxalate kidney stones, collagen can meaningfully increase urinary oxalate excretion (Knight 2006 showed a 43% rise from 30 g of gelatin) (1). In people without stone risk, the physiological rise is handled by normal urinary function and does not typically cause stones. If you have never had a stone and have no family history, the concern is theoretical rather than practical.
Should I stop taking collagen if I have kidney stones?
Discuss with a nephrologist. If your stones were calcium-oxalate type and you have had recurrent episodes, the safest position is to discontinue collagen or restrict to 5 g/day with the mitigation protocol described above. If your stones were another type (uric acid, cystine, struvite, calcium phosphate), the collagen-oxalate concern does not apply and there is no specific reason to discontinue.
How much collagen is safe for someone with a kidney stone history?
If cleared by your nephrologist, 5 g/day rather than 10 g/day. Do not exceed 5 g/day. Take with calcium-containing food. Maintain 2.5+ litres of daily water intake. Consider baseline and follow-up 24-hour urine collections to monitor urinary oxalate.
Does drinking more water prevent collagen-related kidney stones?
High urinary volume is the single strongest lever against calcium-oxalate stone recurrence — a target of 2.5+ litres/day daily output reduces recurrence risk by roughly 50% (4). It does not eliminate the theoretical collagen-oxalate concern but meaningfully mitigates it.
Is marine collagen safer for kidney stones than bovine?
No meaningful difference. Both are similarly high in hydroxyproline (the metabolic precursor to oxalate). Source choice does not obviously affect the oxalate concern.
Can I take UC-II if I have kidney stones?
Yes, likely. UC-II works at ~40 mg/day — three orders of magnitude below hydrolysed collagen doses. The hydroxyproline contribution is trivial and the oxalate concern does not meaningfully apply. UC-II is a legitimate alternative for stone-formers seeking joint benefit specifically (6).
Should I stop dairy or calcium supplements to avoid stones from collagen?
No, and this is important. Higher dietary calcium reduces calcium-oxalate stone recurrence risk (3). Reducing calcium intake is counterproductive. If anything, taking collagen alongside calcium-containing food helps bind dietary oxalate in the gut.
How long does it take for collagen to affect urinary oxalate?
The urinary oxalate rise from hydroxyproline metabolism happens within 24 hours of ingestion (Knight 2006 measured within a 24-hour urine collection) (1). Chronic changes over weeks to months of continuous supplementation are less well characterised. Any monitoring protocol should include a baseline measurement and a repeat at 4–8 weeks.
References
1. Knight J, Jiang J, Assimos DG, Holmes RP. Hydroxyproline ingestion and urinary oxalate and glycolate excretion. Kidney Int 2006. https://pubmed.ncbi.nlm.nih.gov/16988700/
2. Holmes RP, Knight J, Assimos DG. Origin of urinary oxalate. Kidney Int 2016. https://pubmed.ncbi.nlm.nih.gov/27346720/
3. Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997. https://pubmed.ncbi.nlm.nih.gov/9092314/
4. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996. https://pubmed.ncbi.nlm.nih.gov/8632595/
5. Taylor EN, Curhan GC. Diet and fluid prescription in stone disease. Kidney Int 2006. https://pubmed.ncbi.nlm.nih.gov/16820791/
6. Crowley DC, Lau FC, Sharma P, et al.. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci 2009. https://pmc.ncbi.nlm.nih.gov/articles/PMC2764342/